Cithrol™ GMO HP

High purity lipid-based drug delivery excipient offering the potential for enhanced bioavailability of actives coupled with controlled drug release. Its liquid crystalline structure in aqueous systems and ability to enhance membrane penetration enable Cithrol GMO HP to offer sustained drug release and greater active bioavailability for oral and topical dosage forms. Contains a minimum of 92% monoester and 88% oleic acid.